Harmless Bacteria Thrive in Patients with Inflammatory Bowel Disease
By LabMedica International staff writers Posted on 26 May 2015 |
The survival and proliferation of usually harmless Escherichia coli in the gut of inflammatory bowel disease patients may now be better understood, as fundamental mechanism through which the bacteria can thrive during flare-ups has been defined.
Some strains of E. coli normally live in the intestines of humans, and are important for a healthy digestive tract, but for people who suffer from inflammatory bowel diseases (IBD), these innocuous strains may proliferate during a flare-up and further contribute to disease and discomfort.
Scientists at Pennsylvania State University (University Park, PA, USA) and their colleagues studied the interactions between enterobactin, myeloperoxidase and lipocalin 2 and how they regulate E. coli in the intestine. Enterobactin (Ent) is an iron-loving chemical secreted by E. coli that takes iron from host proteins in the body and aids the proliferation of E. coli. Myeloperoxidase (MPO) is an antibacterial protein that white blood cells produce to fight bacteria, however Ent inhibits MPO from doing its job. Lipocalin 2 (Lcn2) is another protein, also produced by white blood cells, that gathers up Ent so that bacteria fail to obtain a sufficient amount of iron for their survival.
Spectral analysis of lactoperoxidase (LPO) during the oxidation of Ent, 2,3-dihydroxybenzoic acid (DHBA) and 4-aminobenzoic hydrazide (ABAH) was recorded at 412 nm using CARY50BIO UV-Visible Spectrophotometer (Agilent Technologies; Santa Clara, CA, USA). By using various techniques the team found that Lcn2 can counter the effects of Ent on MPO. They were able to define a new defense mechanism used by E. coli residing in a human or animal host, the inhibition of MPO by Ent. These findings define a fundamental mechanism by which E. coli surpasses the host innate immune responses during inflammatory gut diseases and gains a distinct survival advantage.
Matam Vijay-Kumar, PhD, an assistant professor of nutritional sciences and medicine and lead author of the study said, “Several types of inflammatory bowel disease are characterized by expansion of the opportunistic E. coli in the gut. However, the mechanisms by which E. coli can thwart the hostile host innate immune system are poorly understood. Identifying these mechanisms will help to reduce the E. coli burden in the inflamed gut and prevent chronic extra-intestinal diseases. We have to find a way to identify the drugs which can inhibit or degrade secreted enterobactin. Alternatively, since MPO is known to be pro-inflammatory not only in IBD but also in other inflammatory diseases, it may be possible to develop enterobactin-based drugs to alleviate inflammatory pathways.” The study was published on May 12, 2015, in the journal Nature Communications.
Related Links:
Pennsylvania State University
Agilent Technologies
Some strains of E. coli normally live in the intestines of humans, and are important for a healthy digestive tract, but for people who suffer from inflammatory bowel diseases (IBD), these innocuous strains may proliferate during a flare-up and further contribute to disease and discomfort.
Scientists at Pennsylvania State University (University Park, PA, USA) and their colleagues studied the interactions between enterobactin, myeloperoxidase and lipocalin 2 and how they regulate E. coli in the intestine. Enterobactin (Ent) is an iron-loving chemical secreted by E. coli that takes iron from host proteins in the body and aids the proliferation of E. coli. Myeloperoxidase (MPO) is an antibacterial protein that white blood cells produce to fight bacteria, however Ent inhibits MPO from doing its job. Lipocalin 2 (Lcn2) is another protein, also produced by white blood cells, that gathers up Ent so that bacteria fail to obtain a sufficient amount of iron for their survival.
Spectral analysis of lactoperoxidase (LPO) during the oxidation of Ent, 2,3-dihydroxybenzoic acid (DHBA) and 4-aminobenzoic hydrazide (ABAH) was recorded at 412 nm using CARY50BIO UV-Visible Spectrophotometer (Agilent Technologies; Santa Clara, CA, USA). By using various techniques the team found that Lcn2 can counter the effects of Ent on MPO. They were able to define a new defense mechanism used by E. coli residing in a human or animal host, the inhibition of MPO by Ent. These findings define a fundamental mechanism by which E. coli surpasses the host innate immune responses during inflammatory gut diseases and gains a distinct survival advantage.
Matam Vijay-Kumar, PhD, an assistant professor of nutritional sciences and medicine and lead author of the study said, “Several types of inflammatory bowel disease are characterized by expansion of the opportunistic E. coli in the gut. However, the mechanisms by which E. coli can thwart the hostile host innate immune system are poorly understood. Identifying these mechanisms will help to reduce the E. coli burden in the inflamed gut and prevent chronic extra-intestinal diseases. We have to find a way to identify the drugs which can inhibit or degrade secreted enterobactin. Alternatively, since MPO is known to be pro-inflammatory not only in IBD but also in other inflammatory diseases, it may be possible to develop enterobactin-based drugs to alleviate inflammatory pathways.” The study was published on May 12, 2015, in the journal Nature Communications.
Related Links:
Pennsylvania State University
Agilent Technologies
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia